VivoSeq
Infectious Disease

Ebola Hemorrhagic Fever

8

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Ebola hemorrhagic fever is an early-stage landscape with 8 programs across 5 companies. The most active players are Pfizer, Appili Therapeutics Inc., Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 6 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

11/100

Mech. Concentration

13/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1A

Appili Therapeutics Inc.

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

2 programs

ApprovedGilead logo

Gilead

1 program

ApprovedSanofi logo

Sanofi

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Not yet recruiting2 · 100%

Clinical Trials

Trial Activity

Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRC
Not yet recruiting·IInstitute of Tropical Medicine, Belgium·N/A·NCT07688083·100 enrolled
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA
Not yet recruiting·IInstitute of Tropical Medicine, Belgium·N/A·NCT07681752·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)